cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.15468/dl.mycwx3
title: Occurrence Download

description: A dataset containing 102 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is Xanthium strumarium",
 "Country is Brazil",
 "HasCoordinate is true"
 ]
}

 The dataset includes 102 records from 35 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0020289-250827131500795/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.25934/pr00008688
title: Risk of therapy-related adverse events in men on abiraterone or enzalutamide, a IPD meta-analysis of clinical trial data 

description: Background: Prostate cancer (PCa) is the most common cancer and second leading cause of death among men; over 260,000 men are diagnosed yearly and nearly 35,000 will die from the disease. Patients receive first generation androgen deprivation therapy. First-generation androgen deprivation therapy (ADT) blocks the secretion of testosterone and other androgens and is first-line therapy. PCa requires testosterone (an androgen) in order to grow, by depriving the body of the androgen testosterone (the male sex hormone) ADT may slow the cancer’s growth and temporarily shrink the cancer. However, PCa patients are at increased risk of therapy-related adverse events (AEs), including cardiovascular disease (CVD) outcomes. The introduction of newer agents called androgen receptor targeted (ART) drugs to ADT may further increase therapy-related AE and CVD risk. ARTs work in two ways, either by blocking the site (androgen receptor) on the tumor so it cannot receive androgens (enzalutamide) depriving the tumor of androgens or by blocking androgen synthesis (abiraterone); both means decrease a tumor’s ability to grow. There is no clear recommendation in clinical guidelines to recommend one drug over the other, and the choice of treatment options complicates clinical decision-making. This trial will conduct a comparative analysis using established statistical methods and develop guidance from this analysis to aid clinician decision-making and thereby enhancing patient care. Is there a difference in outcomes according to patient type based on drug received? Alternatively, are the outcomes similar for all patients regardless of drug choice?
DOI: 10.15468/dl.945497
title: Occurrence Download

description: A dataset containing 9452 species occurrences available in GBIF matching the query:
{
 "and" : [
 "HasCoordinate is true",
 "HasGeospatialIssue is false",
 "TaxonKey is Bombus californicus"
 ]
}

 The dataset includes 9452 records from 37 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0020291-250827131500795/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.25934/00004778
title: A Phase 2 Open-Label, Randomized, Multi-center Study of Neoadjuvant Abiraterone Acetate (CB7630) Plus Leuprolide Acetate and Prednisone Versus Leuprolide Acetate Alone in Men With Localized High Risk Prostate Cancer

description: The purpose of this study is to evaluate safety and efficacy of abiraterone acetate plus leuprolide acetate and prednisone, versus leuprolide acetate alone in male participants with prostate cancer (a disease in which cells in the prostate gland become abnormal and start to grow uncontrollably, forming tumors) who are suitable candidates for prostatectomy (surgery to remove all or part of the prostate gland).
DOI: 10.25934/00004798
title: A Randomized, Open-Label, Neoadjuvant Prostate Cancer Trial of Abiraterone Acetate Plus LHRHa Versus LHRHa Alone

description: The goal of this clinical research study is to find out how treatment with abiraterone acetate in combination with prednisone and a Luteinizing Hormone-Releasing Hormone (LHRH) analogue changes the tumor in comparison to treatment with an LHRH analogue alone. Objectives: Primary Objective: To assess the difference in pathologic stage < pT2 between Group A and Group B. Secondary Objective:   -  To assess and compare the changes in levels of androgens (pre, during, and post treatment) in the serum, primary tumor microenvironment and bone marrow between Group A and Group B.   -  To assess changes in biomarkers related to androgen signaling and other cancer-related pathways between Group A and Group B.   -  To assess the difference in rate of positive surgical margins between Group A and Group B.   -  To assess the safety profile of abiraterone acetate and low dose prednisone in a preoperative setting.
DOI: 10.25934/00004828
title: A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease

description: The purpose of this study is to show that abiraterone acetate plus prednisone added to the current standard of care, gonadotropin-releasing hormone (GnRH) decreases prostate specific antigen (PSA) and prolongs the time until it is evident that the cancer has grown. Additionally, safety information about abiraterone acetate in combination with prednisone will be collected. This will include looking at what side effects occur, how often they occur, and for how long they last.
DOI: 10.25934/00004839
title: An Open-Label Study to Determine the Short-Term Safety of Continuous Dosing of Abiraterone Acetate and Prednisone in Modified Fasting and Fed States to Subjects With Metastatic Castration-Resistant Prostate Cancer

description: The purpose of this study is to establish the safety profile of oral (by mouth) abiraterone acetate and oral prednisone following short-term administration after standardized low-fat or high-fat meals to patients with metastatic (spreading) castration-resistant prostate cancer (mCRPC).
DOI: 10.25934/00004876
title: A Prospective Registry of Patients With a Confirmed Diagnosis of Adenocarcinoma of the Prostate Presenting With Metastatic Castrate-Resistant Prostate Cancer

description: The purpose of this registry is to document the characteristics and management of patients with metastatic castrate resistant prostate cancer (mCRPC) in routine clinical practice, independent of treatment used. Given the rapidly evolving landscape in mCRPC treatments, there is a need for a current and improved understanding of how these treatments fit into the current treatment paradigm for mCRPC, how they are combined and sequenced, and how their relative effectiveness profiles emerge outside of a clinical trial setting. This will be based on documentation and description of sequencing of treatment initiation, termination, and duration; relative effectiveness of treatments; defined medical resource utilization (MRU) and quality-of-life parameters and follow-up for survival.
DOI: 10.25934/00005170
title: A Phase I/II Open Label Study of the 17α-Hydroxylase/ C17,20 Lyase Inhibitor, Abiraterone Acetate in Patients With Prostate Cancer Who Have Failed Hormone Therapy

description: The purpose of this study is to determine the maximum tolerated dose and evaluate the safety, tolerability, and activity at the recommended dose (maximum tolerated dose [MTD]) of abiraterone acetate (also known as CB7630) in participants with hormone refractory prostate (gland that makes fluid that aids movement of sperm) cancer (HRPC).
DOI: 10.25934/00005172
title: A Phase 2 Open Label Study of Abiraterone Acetate (JNJ-212082) and Prednisolone in Patients With Advanced Prostate Cancer Who Have Failed Androgen Deprivation and Docetaxel-Based Chemotherapy.

description: The purpose of this study is to assess the safety and efficacy in Korea or Taiwan of oral abiraterone acetate and oral prednisolone in men with metastatic-castration resistant prostate cancer (mCRPC) and with disease progression following treatment with a docetaxel-containing chemotherapy.
DOI: 10.25934/00005173
title: A Phase II Open Label Study of CB7630 (Abiraterone Acetate) in Patients With Advanced Prostate Cancer Who Have Failed Androgen Deprivation and Docetaxel-Based Chemotherapy

description: The purpose of this study is to assess the anti-tumor activities and safety of abiraterone acetate in participants with prostate cancer (a disease in which cells in the prostate gland [a gland in the male reproductive system found below the bladder and in front of the rectum] become abnormal and start to grow uncontrollably, forming tumors) who have failed taxane (docetaxel)-based chemotherapy.
DOI: 10.25934/00005174
title: Phase I/II Open Label Dose Escalation Study of the 17α-Hydroxylase/ C17,20-Lyase Inhibitor, Abiraterone Acetate in Hormone Refractory Prostate Cancer

description: The purpose of this study is to evaluate the safety, pharmacokinetics, pharmacodynamics, and anti‑tumor activities of abiraterone acetate (also referred to as CB7630) in patients with hormone refractory prostate cancer (HRPC).
DOI: 10.25934/00005176
title: An Observational Study of Continuous Oral Dosing of an Irreversible CYP17 Inhibitor, Abiraterone Acetate (CB7630), in Castration-Resistant Prostate Cancer Patients Evaluating Androgens and Steroid Metabolites in Bone Marrow Plasma

description: The purpose of this study is to investigate the effect of abiraterone acetate on levels of androgens and steroid metabolites in bone marrow plasma of patients with metastatic castration-resistant prostate cancer (CRPC).
DOI: 10.25934/00006462
title: A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate (JNJ-212082) Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer

description: The purpose of this study is to demonstrate the safety and effectiveness of abiraterone acetate when co-administered with prednisone in patients with chemo-naive metastatic castration resistant prostate Cancer (mCRPC).
DOI: 10.25934/pr00007473
title: A Phase I, Open-label, Dose-finding Study of GSK2636771 Administered in Combination With Enzalutamide (Xtandi^TM ) in Male Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

description: This Phase I, open-label, dose-finding, multicenter study is designed to determine the recommended Phase II dose (RP2D) for the combination of an orally administered Phosphatidylinositol-4,5-bisphosphate 3-kinase beta (PI3K-beta) inhibitor (GSK2636771) with enzalutamide. Subjects with phosphatase and tensin homolog (PTEN)-deficient metastatic castration-resistant prostate cancer (mCRPC) who are receiving a stable dose of enzalutamide with a recently demonstrated progression (either by RECIST [Response Evaluation Criteria In Solid Tumors] version 1.1, prostate-specific antigen [PSA] progression, and/or progression in bone) per the Prostate Cancer Working Group 2 (PCWG2) criteria will be enrolled. Eligible subjects will be enrolled in the Dose-Escalation Phase to determine the maximum tolerated dose (MTD) of the combination therapy using a modified 3+3 dose escalation procedure. The safety, pharmacokinetics (PK) and clinical efficacy will also be assessed to guide the selection of the RP2D. The starting dose will be GSK2636771 300 mg once daily in combination with the recommended dose (160 milligram [mg] once daily) of oral enzalutamide. Once the RP2D has been established, additional subjects will be enrolled in the Dose Expansion Phase to further evaluate the safety, PK and preliminary clinical activity. Safety assessments will be performed throughout the study including physical examinations, vital signs, clinical laboratory tests, 12 lead electrocardiograms and monitoring of adverse events. Blood samples will be collected for pharmacokinetic analysis. Subjects will continue treatment until an unacceptable toxicity, disease progression, withdrawal of consent or death occurs. A post-treatment follow-up visit will be performed within 30 days of the last dose of study treatment. Xtandi is a registered trademark of Astellas Pharma Inc
DOI: 10.25934/pr00007750
title: A Phase 3 Randomized, Placebo-controlled Double-blind Study of JNJ-56021927 in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Subjects With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)

description: The purpose of this study is to compare the radiographic progression-free survival (rPFS) of apalutamide in combination with abiraterone acetate (AA) plus prednisone or prednisolone (AAP) and AAP in participants with chemotherapy-naive (participants who did not receive any chemotherapy [treatment of cancer using drugs]) metastatic castration-resistant prostate cancer (mCRPC) (cancer of prostate gland [gland that makes fluid that aids movement of sperm]).
DOI: 10.25934/00004855
title: A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate (JNJ-212082) Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Docetaxel-Based Chemotherapy

description: The purpose of this study is to evaluate the safety and efficacy of abiraterone acetate when co-administered with prednisone in Asian patients with metastatic castration-resistant prostate cancer (mCRPC) who have failed docetaxel-based chemotherapy.
DOI: 10.25934/00005171
title: A Phase II Open Label Study of CB7630 (Abiraterone Acetate) and Prednisone in Patients With Advanced Prostate Cancer Who Have Failed Androgen Deprivation and Docetaxel-Based Chemotherapy

description: The purpose of this study is to evaluate the efficacy and safety of abiraterone acetate in participants with advanced prostate cancer (a disease in which cells in the prostate gland become abnormal and start to grow uncontrollably, forming tumors).
DOI: 10.25934/00005175
title: A Phase II Study of JNJ-212082 (Abiraterone Acetate) in Metastatic Castration-Resistant Prostate Cancer Patients Who Have Received Docetaxel-based Chemotherapy

description: The purpose of this study is to investigate the safety and efficacy of abiraterone in participants with metastatic castration-resistant prostate cancer (mCRPC) who have received docetaxel-based chemotherapy (treatment of disease, usually cancer, by chemical agents).
DOI: 10.25934/00005177
title: A Randomized Phase 2 Study Evaluating Abiraterone Acetate With Different Steroid Regimens for Preventing Symptoms Associated With Mineralocorticoid Excess in Asymptomatic, Chemotherapy-naïve and Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients

description: The purpose of the study is to determine the safety and clinical benefit of the combinations of abiraterone acetate and prednisone or abiraterone and dexamethasone in prostate cancer patients. Prednisone will be given at one of three different dose schedules. Dexamethasone will be given at one dose schedule. This will include looking at what side effects occur and how often they occur. In addition the impact of the study drug on quality of life and pain will be evaluated. The study will also collect data on subsequent treatment of patients after they come off the study drug (approximately 4.5 years after the start of study treatment of the first subject participating in the study). By analyzing blood samples, the study aims to identify if some markers could help to understand if the treatment with abiraterone is effective and also help to understand if patients can become resistant.
DOI: 10.25934/pr00008388
title: A Randomized, Open Label, Multicenter Study of Cabazitaxel Versus an Androgen Receptor (AR)-Targeted Agent (Abiraterone or Enzalutamide) in mCRPC Patients Previously Treated With Docetaxel and Who Rapidly Failed a Prior AR-targeted Agent (CARD)

description: Primary Objective: To compare the radiographic progression-free survival (rPFS) (using Response Evaluation Criteria in Solid Tumors [RECIST] 1.1 for tumor lesions and Prostate Cancer Working Group 2 (PCWG2) criteria for bone scan lesions or death due to any cause) with chemotherapy (cabazitaxel plus prednisone, Arm A) versus Androgen Receptor (AR)-targeted therapy (enzalutamide or abiraterone acetate plus prednisone, Arm B) in mCRPC participants who have been treated with docetaxel and who had disease progression while receiving AR-targeted therapy within 12 months of AR treatment initiation (less than or equal to [<=]12 months, either before or after docetaxel). Secondary Objective:   -  To compare efficacy for:   -  Prostate-specific antigen (PSA) response rate and time to PSA progression (TTPP).   -  Progression-free survival (PFS).   -  Overall survival (OS).   -  Tumor response rate and duration of tumor response.   -  Pain response and time to pain progression.   -  Symptomatic skeletal event (SSE) rate and time to occurrence of any SSE.   -  Health status and Health-related Quality of Life (HRQOL).   -  To evaluate the correlation of a signature of resistance to AR-targeted agents with clinical outcome via the analysis of circulating tumor cell (CTC) phenotypes as well as expression and localization of proteins including AR isoforms in CTCs.   -  To evaluate safety in the 2 treatment arms.
DOI: 10.15468/dl.kqczun
title: Occurrence Download

description: A dataset containing 14 species occurrences available in GBIF matching the query:
{
 "and" : [
 "Geometry POLYGON((0.31888 36.93066,35.68112 36.93066,35.68112 51.06934,0.31888 51.06934,0.31888 36.93066))",
 "HasCoordinate is true",
 "HasGeospatialIssue is false",
 "OccurrenceStatus is Present",
 "TaxonKey is Herilla pavlovici"
 ]
}

 The dataset includes 14 records from 3 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0020290-250827131500795/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.qj9nkb
title: Occurrence Download

description: A dataset containing 1125 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is Alchornea cordifolia",
 "HasCoordinate is true",
 "BasisOfRecord is Human Observation"
 ]
}

 The dataset includes 1125 records from 70 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0020292-250827131500795/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.qhsj85
title: Occurrence Download

description: A dataset containing 32 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is Xanthium strumarium",
 "Country is Bulgaria",
 "HasCoordinate is true"
 ]
}

 The dataset includes 32 records from 7 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0020293-250827131500795/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.ffhwuq
title: Occurrence Download

description: A dataset containing 1 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is Xanthium strumarium",
 "Country is Burundi",
 "HasCoordinate is true"
 ]
}

 The dataset includes 1 records from 1 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0020294-250827131500795/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.cmxerf
title: Occurrence Download

description: A dataset containing 6090 species occurrences available in GBIF matching the query:
{
 "TaxonKey" : [
 "is Elymus tsukushiensis"
 ]
}

 The dataset includes 6090 records from 179 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0020295-250827131500795/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.rpex46
title: Occurrence Download

description: A dataset listing the 117 species recorded in GBIF matching the query:
{
 "and" : [
 "Country is Colombia",
 "OccurrenceStatus is Present",
 "TaxonKey is Testudines"
 ]
}

 The dataset's 117 records were derived from 360 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0020287-250827131500795/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.tunrcg
title: Occurrence Download

description: A dataset containing 0 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is one of (Hantzschia amphioxyss, Hapalosiphon, Heteroleibleinia, , Hippodonta, Homoeothrix, Kirchneriella, Klebsormidium, Kobayasiella, Kobayasiella subtilissima, Lagerheimia, Lemnicola, , Luticola goeppertiana, Dorofeyukea, Lyngbya, Melosira, Melosira varians, Merismopedia, Micractinium, Micrasterias, Microcystis, Monoraphidium, Mougeotia, Navicula angusta, Navicula antonii, Navicula capitatoradiata, Navicula cincta, Navicula cryptocephala, Navicula cryptotenelloides, Navicula erifuga, Navicula germainii, Navicula gregaria, Navicula heimansioides, Navicula libonensis, Navicula longicephala, Navicula minima, Navicula, Navicula notha, Navicula radiosa, Navicula ranomafanensis, Navicula recens, Navicula reichardtiana, Navicula rhynchocephala, Navicula riediana, Navicula rostellata, Navicula schroeteri, Navicula symmetrica, Navicula tripunctata, Navicula trivialis, Navicula veneta, Navicula zanoni, Navicymbula, Nitzschia, , Nitzschia agnewii, , Nitzschia archibaldii, Nitzschia aurariae, Nitzschia capitellata, , Nitzschia closterium, Nitzschia desertorum, Nitzschia dissipata, Nitzschia etoshensis, Nitzschia filiformis, , , Nitzschia intermedia, Nitzschia irremissa, Nitzschia liebetruthii, , Nitzschia littorea, , , Nitzschia nana, Nitzschia pura, , Nitzschia recta, Nitzschia sublinearis, Nitzschia communis, Nostoc, Nostoc commune, Oedogonium, Oedogonium minus, Oocystis, Orthoseira, Oscillatoria, Oscillatoria princeps, Oscillatoria sancta, Oscillatoria tenuis, Oxyneis, Palmella, Pediastrum, Pediastrum duplex, Phacus, Phormidium, Pinnularia acrosphaeria, Pinnularia, )",
 "HasCoordinate is true",
 "HasGeospatialIssue is false",
 "BasisOfRecord is one of (Specimen, Living Specimen, Observation, Human Observation, Machine Observation, Material sample, Literature Occurrence, Material citation, Occurrence evidence)",
 "Geometry POLYGON ((35.628 -23.023,35.6007 -22.9702,35.6007 -23.165,35.628 -23.023))"
 ]
}

 The dataset includes 0 records from 0 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0020297-250827131500795/datasets/export for details.
DOI: 10.6084/m9.figshare.30025648
title: <b>Perceived Family Support and Undernutrition among Older Outpatients of a Northern Nigerian Hospital</b>

description: A mixed-methods study among 145 older adults in Kano found a 15.2% prevalence of undernutrition and 36.6% prevalence of poor family support. Undernutrition was strongly associated with age ≥75 years (aOR=22.59) and poor family support (aOR=9.31). Qualitative findings highlighted poor family interaction, financial hardship, and limited food variety as key contributors. Strengthening family support networks is critical to improving nutrition and health outcomes among older adults.
DOI: 10.6084/m9.figshare.30025648.v2
title: <b>Perceived Family Support and Undernutrition among Older Outpatients of a Northern Nigerian Hospital</b>

description: A mixed-methods study among 145 older adults in Kano found a 15.2% prevalence of undernutrition and 36.6% prevalence of poor family support. Undernutrition was strongly associated with age ≥75 years (aOR=22.59) and poor family support (aOR=9.31). Qualitative findings highlighted poor family interaction, financial hardship, and limited food variety as key contributors. Strengthening family support networks is critical to improving nutrition and health outcomes among older adults.